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Biphasic increase in circulating and renal TNF-a in MRL-lpr
mice with differing regulatory mechanisms
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Biphasic increase in circulating and renal TNF-a in MRL-lpr mice with
differing regulatory mechanisms. Tumor necrosis factor (TNF)-a contrib-
utes to expansion of lymphocytes in neonatal mice and can accelerate
renal injury. T cells induced by the lpr gene promote renal injury.
However, the lpr gene alone is insufficient to cause renal damage, since
MRL-lpr, but not C3H-lpr mice develop lupus nephritis. In this study, we
examined the temporal expression of TNF-a in the kidney and circulation
of mice (MRL and C3H) with the lpr gene and their congenic counterparts
(+ +). We measured a bioactive TNF-a using L929 cells and tissue
expression with an avidin-biotin immunoperoxidase method. A biphasic
increase in circulating TNF-a in MRL-lpr mice was detected. There was an
initial peak in neonatal mice (703 208 pg/mI) which normalized by two
months of age (87 13 pg/ml) and reascended proportional to the severity
of renal injury (non-proteinuric 570 87, proteinuric; 1255 135 pg/ml).
In addition, there was only a single peak in neonatal C3H-lpr mice (1270
318 pg/mI) with a nadir by six weeks of age (434 52 pg/mI). In
contrast, serum TNF-a was low in MRL- + + and C3H- + + mice (80 3
and 95 30 pg/ml), respectively. TNF-a expression in kidneys paralleled
the serum pattern in MRL-lpr mice. Enhanced TNF-a expression was
restricted to tubular epithelial cells (TEC) in neonatal MRL-lpr and
C3H-lpr mice, and not detected in congenies. In adult mice, intrarenal
TNF-a expression was more ubiquitous and was detected in glomeruli,
vascular smooth muscle and perivascular infiltrating cells as well as TEC.
In addition, TNF-a expression intensified in the kidneys in proportion to
the severity of proteinuria. TNF-a was absent in age matched C3H-lpr,
C3H-+ + and MRL-+ + mice. Additional studies indicated that: (1)
neither MRL-lpr or C3H- + + TEC constitutively secreted substantial
amounts of TNF-a and required a cytokine stimulation; and (2) the
clearance of TNF-a via TNF-n receptors was similar in MRL-lpr,
MRL- + + and C3H- + + mice, suggesting the increase of serum TNF-a
was not a result of a defect in clearance. Thus, these results indicate two
distinct mechanisms of TNF-a regulation in MRL-lpr mice: (1) neonatal
up-regulation related to the lpr gene; and (2) an increase in mature mice
proportional to the severity of lupus nephritis.
Enhanced expression of cytokines contribute to the initiation
and progression of the autoimmune tissue injury [1, 21. An
increase in multiple cytokines within the kidney of mice with
autoimmune renal disease raised the possibility that cytokine
expression promoted renal injury. Our previous studies estab-
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lished that an increase in the tumor necrosis factor (TNF)-a and
interleukin (IL)-1 in the kidneys of autoimmune MRL-lpr mice
was detrimental, since these cytokines increased in proportion to
progressive tissue damage and delivery of either into autoimmune
prone mice contributed to the acceleration of progressive renal
damage [31. The concept that an increase in cytokines may be
instrumental in autoimmune renal disease is not limited to the
MRL-lpr strain; numerous reports in other autoimmune mice
(NZB x NZW Fl hybrid) and patients with systemic lupus
erythematosus (SLE) document increases in several cytokines
including, not only TNF-a and IL-i, but IL-6 and interferon
(IFN)-y [4—71.
The interaction of the lpr gene and the MRL strain background
causes autoimmune renal disease. Neither the lpr gene alone nor
the MRL background causes the fulminant autoimmune renal
injury in MRL-lpr mice [8, 9]. Loss of renal function in MRL-lpr
mice is obvious by three to four months of age, and progresses
rapidly resulting in death by five to six months of age [8]. By
comparison, congenic MRL-+ + mice, lacking the lpr gene,
express only a mild, indolent renal injury in the second year of life,
while other strains with the lpr gene share abnormal serological
features and hematopoietic cells characteristic of MRL-lpr mice,
but are not compromised by kidney injury [I Therefore, using
several strains with the lpr mutation allows us to determine
whether a change in cytokine expression is related to the presence
of lpr alone exclusive of renal injury.
While the increased expression of cytokines in the kidney
during progressive tissue damage can be attributed to a chronic
inflammatory process, the detection of cytokines in neonatal mice
suggests the possibility that cytokine dysregulation may be central
in the initiation of autoimmune tissue destruction. We previously
established that newborn MRL-lpr mice express heightened levels
of circulating macrophage stimulating factor-i (CSF-l), while
others report an elevation of serum IL-6 several weeks after birth
[5, 10]. Furthermore, we have detected increased amounts of
CSF-i transcripts in the kidneys of MRL-lpr mice at one month of
age, well in advance of renal injury [10, ii].
In this study we have investigated the temporal expression of
TNF-a in the serum and in the kidney of MRL-lpr mice and
identify the intrarenal cells expressing this cytokine beginning in
neonates and extending throughout the progression of renal
disease. Since the genetic and molecular analyses of the mouse
Fas gene indicated that Fas is encoded by the gene at the locus of
the mouse mutant lpr, and since the Fas antigen and ligand belong
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to the TNF receptor and TNF family, the relationship between
TNF-a and the presence of lpr was also examined [12—16]. We
now report that there is a biphasic increase in TNF-a in the serum
and kidney of MRL-lpr mice with differing regulatory mecha-
nisms; the increase in the second phase is proportional to the
degree of renal damage. In addition, we establish that the increase
in circulating TNF-a was not caused by a defect in the clearance
of this cytokine prior to renal injury, and that up-regulation of the
expression of TNF-a in TEC isolated from normal or MRL-lpr
mice is similar and requires a stimulus to increase production.
Methods
Mice
Female MRLIMpJ-lpr/lpr (MRL-/pr), MRL/MpJ-+/+ (MRL-
++), C3H/Fej and C3H/Hej (C3H-++), C3H/Hej-lprllpr (C3H-
lpr) and BALB/c mice were purchased from The Jackson Labo-
ratory (Bar Harbor, ME, USA) and bred and maintained in our
facilities. Sera samples were stored at —70°C until TNF-a was
measured.
Reagents
Tissue culture media were from Gibco (Grand Island, NY,
USA) and chemicals were obtained from Sigma Chemical Co. (St.
Louis, MO, USA). Recombinant mouse TNF-a was provided
from Genentech (South San Francisco, CA, USA) and recombi-
nant human TNF-a was purchased from Genzyme (Cambridge,
MA, USA). Rabbit anti-mouse TNF-a antibody was a gift from
Dr. A. Cerami (Picower Institute for Medical Research, Manhas-
set, NY, USA [17]). Antibody specificity for TNF-a was confirmed
by Western blot analysis [18] and by the neutralization of L929 cell
bioassay.
TNF-a L929 cell bioassay
We determined TNF-a activity in the sera and culture super-
natants by a standard cytotoxicity assay using L929 mouse fibro-
blasts [American Type Culture Collection (ATCC), Rockville,
Maryland, USA] [19]. Briefly, we plated 5 to 7 X io L929
cells/well into 96-well flat bottom plates (Costar, Cambridge, MA,
USA), then added the sera or supernatants to wells containing an
equal volume of RPM! 1640 media with 10 jg/ml of actinomycin
D. These cultured supernatants were added undiluted or diluted
at 1:2, 1:4, and 1:8. The initial serum samples were diluted 1:10 (or
20 p1/well). We incubated the plates for 24 hours at 37°C in a
humidified chamber with 5% CO2. then removed the media, and
added 0.1% crystal violet in methanol to each well for 20 minutes.
After rinsing with distilled water, we added 100 p1 of 0.5% SDS to
each well. Each sample was analyzed in triplicate. The standard
curve was generated by using serial dilutions of murine recombi-
nant TNF-a (100 to 0.4 pg of TNF-c/well/200 pJ or 500 to 2
pg/mi). TNF-a activity was neutralized with anti-TNF-a antibody
(100 ng/ml). Optical densities were read on a 96-well microtiter
plate reader at 570 nm (Vmax kinetic microplate reader, Molec-
ular Devices Corp., Menio Park, CA, USA). The lowest detect-
able level was 10 pg/ml.
Immunohistochemical detection of TNF-a
TNF-a was localized in tissue sections using immunohistochem-
ical techniques. We fixed tissues in 10% phosphate-buffered
formalin, embedded in paraffin and detected TNF-a with an
immunoperoxidase technique. Briefly, we blocked endogenous
peroxidase activity with 0.6% hydrogen peroxide and 0.2% so-
dium azide for 10 minutes, and then washed the tissue sections
several times with 0.01 M Tris, pH 7.4, 0.85% NaC1 (TBS)
containing 0.1% bovine serum albumin (BSA) followed by per-
meabilization with bovine testicular hyaluronidase (1 mg/mI in 0.1
M sodium acetate, pH 5.5) for 30 minutes in a humidified chamber
at 37°C. To block endogenous avidin and biotin we used an
Avidin/Biotin blocking kit (Vector Laboratories, Inc., Burl-
ingame, CA, USA). The sections were then incubated with
anti-murine TNF-a antibody (1:150 dilution) in a humidified
chamber for two hours at room temperature, washed extensively
and exposed to biotinylated goat anti-rabbit IgG antibody for one
followed by avidin-peroxidase complex using the Vectastain ABC
Elite Kit (Vector Laboratories). Sections were then exposed to
3-3'-diaminobenzidine (0.5 mg/ml in TBA containing 0.015%
H202) for a chromogenic reaction and counterstained with methyl
green-alcian blue. Specificity controls included the replacement of
primary antibody with normal rabbit IgG and the incubation with
the anti-murine TNF-a antibody neutralized with a 20-fold molar
excess of TNF-a (Genentech, South San Francisco, CA, USA).
Sections were also stained for alkaline phosphatase to identify the
brush border of proximal TEC using the Vector Red ALP reagent
kit (Vector Laboratory).
Cell culture and cell lines
Renal TEC lines derived from C3H/Fej mice (CS3.1) and
MRL-lpr mice (M3.1) were transfected with antigen defective
SV4O and characterized as previously described [20]. TEC were
cultured in Ki medium (1:1 mixture of DMEM4.5 and Ham's F12
medium), containing 5% fetal calf serum (FCS), 1% penicillin and
streptomycin and hormonal additives. We obtained P388D1
(p388) cells from the ATCC, and these cells were cultured in
RPMI164O with 10% FCS and 1% penicillin and streptomycin.
Primary TEC cultures from MRL-lpr and C3H/Fej mice were
prepared beginning at three months of age by sequential sieving
techniques as previously reported [20]. Primary TEC cultures
from each kidney were plated on four collagen-coated 100 mm
dishes (day 0), the medium was exchanged on day 5 and the cells
were transferred onto collagen-coated 24 well plates (Falcon, 1 X
105/well) three days later.
Preparation of conditioned medium
All cell lines and primary cells were grown in 24 well plates
seeded at a density of 1 X 105/well for 24 hours, in K1 media.
After the cells were confluent, we replaced Ki media with
DMEM1.0 media without FCS three times during the next 24
hours to synchronize the cell cycle at the G0 stage. Finally,
DMEMI.0 or DMEM1.0 containing LPS (1 Lg/ml), IL-la (100
ng/ml) or CSF-1 (10 ng/ml) was added, and the supernatants were
collected after 24 hours and stored at —70°C.
In vivo clearance of exogenous recombinant murine and
human TNF-a
Since mouse TNF-R1 binds to both mouse and human TNF,
while mouse TNF-R2 binds exclusively to mouse TNF [21], we can
determine whether the TNF-a clearance is related to the 55 kDa
receptor (TNF-R1) and/or the 77 kDa receptor (TNF-R2). There-
fore, either recombinant mouse (250 ng/mouse) or human TNF-a
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(500 ng/mouse) was i.p. injected into C3H-++, MRL-++ and
MRL-lpr mice two months of age (N = 5/group). In preliminary
study, several doses of mouse or human TNF-a were injected to
determine the adequate dose for the clearance study. Mice two
months of age were chosen for injection since serum TNF-a levels
before injection and renal function were similar in three strains.
Mice were bled at 30, 60, 120 and 180 minutes later. Bioactive
TNF-a levels were measured by a L929 assay.
Statistics
We performed statistical analysis using Statview SE+ (Abacus
Concepts, Berkeley, CA, USA), by comparing the differences
between groups using a one way ANOVA, unpaired t-test,
Wilcoxon single-rank sum test, Fisher's exact test, or Pearson's
correlation coefficient for the analysis of parametric and non-
parametric data. All results were expressed as mean SEM.
Results
Circulating TNF-a was increased biphasically in MRL-lpr as
compared to MRL- + + and C3H- + + mice
There was a biphasic increase in bioactive TNF-a levels in the
serum of MRL-/pr mice as compared to MRL-+ + and C3H-+ +
mice (Fig. 1). Circulating levels of TNF-a initially peaked in
neonatal mice (day 7), normalized by two months of age, and then
reascended continually and steadily throughout the remaining
lifespan. A comparison of serum TNF-a in MRL-lpr mice two to
six months of age indicated that mice that became proteinuric had
substantially higher serum TNF-a levels as compared to non-
proteinuric mice (Fig. 1A). In fact, although there was a modest
increase in serum TNF-a in neonatal MRL- + + (4 times less than
MRL-lpr), this increase was transient and circulating TNF-a in
MRL-+ + was barely detectable after this initial rise. A compar-
ison of serum TNF-c levels of MRL-+ + at six months of age with
several normal strains age and sex matched, including C3H/Fej,
C3H/Hej (Fig. 1B) and BALB/c indicated they were similar (80
3 pg/ml, 95 23 pg/ml, 134 22 pg/mI, respectively; N =
5/group). There was a positive correlation between the amount of
serum TNF-a and the degree of proteinuria (r = 0.84, P < 0.001,
N = 22). Serum TNF-a detection was specific since L929 cell
cytotoxicity was completely neutralized with anti-TNF-a antibody.
Elevated serum TNF-a in neonates is associated with the
presence of lpr
Circulating TNF-a levels was higher in C3H-lpr mice as com-
pared with age- and sex-matched normal C3H/Fej or C3H/Hej
mice. Circulating TNF-a levels in C3H-lpr mice peaked in neo-
natal mice (day 7), declined to a nadir by six weeks of age and
never reascended (Fig 1B). However, detectable levels of serum
TNF-a in C3H-lpr mice were three to five times higher than C3H
mice lacking the lpr gene. The serum TNF-a in C3H/Fej and
C3H/Hej remained minimal and stable from one week through six
months of age (Fig. 1B). Since there was no difference between
serum TNF-a levels in C3H/Fej and C3H/Hej, we refer to these
mice as C3H-++.
Age, months
Fig. 1. Semm TNF-a was increased in MRL-lpr and C3H-lpr mice as
compared to congenic strains. We determined TNF-a activity using a
standard L929 mouse fibroblasts cytotoxicity assay. A. There was a
biphasic increase in circulating TNF-a in MRL-lpr mice. TNF-a was
compared in proteinuric and non-proteinuric MRL-lpr mice beginning at
5 months of age. There was a marked elevation of circulating TNF-a in
proteinuric MRL-lpr mice. Values are expressed as x SEM proteinuric
MRL-lpr (U, N = 6), non-proteinuric MRL-lpr (, N = 3—9) and
MRL-+ + (D, N = 3—5), (MRL-lpr proteinuric and non-proteinuric vs.
MRL-++), * <0.05, <0.01, ***p < 0.005. B. Serum TNF-a levels
were elevated in neonatal C3H-lpr mice as compared to normal C3H/Fej
and C3H/Hej mice. C3H-lpr (N = 3—5), C3H/Hej (N = 4), and C3H/Fej(N = 3—5). C3H-lpr vs. C3H/Fej and C3HJHej, < 0.01, < 0.001.
Renal TNF-a expression is enhanced in neonatal MRL-lpr and
C3H-lpr mice as compared with MRL- + + and C3H- + + mice
exclusively in TEC
We investigated the temporal pattern of TNF-a expression in
the kidneys of neonatal MRL-lpr, MRL- + +, C3H-lpr and
C3H-+ + mice. There was a greater expression of TNF-a in
cortical and medullary TEC in MRL-lpr and C3H-lpr mice during
the first week of life as compared to their congenic counterparts
(Fig. 2, Table 1). The increase TNF-a was higher in the cortex
than medulla. Since the brush border are poorly developed in
neonatal mice, we were unable to detect the alkaline phosphatase
reaction product. Increased TNF-a expression was transient in
TEC of MRL-/pr mice, and decreased dramatically by the second
week of life (Table 1). This enhanced expression of TNF-cs in
neonates was limited to the TEC, since the level of TNF-a in the
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Fig. 2. Localization of TNF-a in the kidney in neonatal and adult MRL-lpr mice. TNF-a was detected by the avidin-biotin immunoperoxidase method
using polyclonal rabbit anti-murine TNF-a antibody. A. An increase in TNF-cs was detected in cortical TEC (3+) from MRL-lpr mice (5 days). (X 100)
B. TNF-a was barely detectable in TEC from MRL-+ + mice (7 days). (X 250) C. Proteinuric MRL-lpr mice (6 months) expressed TNF-a in the cortical
TEC (Grade = 3+), glomeruli (Grade = 2), and perivascular mononuclear cell infiltrates (arrow, Grade = 3+ focal). (X 500) Insert upper right. In
this glomerulus TNF-a is detected in epithelial cells (arrows) and mesangial cells (X 1000). D. TNF-a is barely detectable in C3H/Fej mice (5 months)
(x 250).
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Fig. 2. Continued.
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Table 1. Enhanced TNF-o in the kidneys of neonatal MRL-lpr and
C3H-lpr mice
Strain
Age
day N
TEC
CortexC Medulla
MRL-lpr 1—3
4—7
10—14
2
5
8
2.5(F)3iP
1.5
1.2
0.8
0.4
MRL-++ 1-3
4—7
10-44
5
4
2
1.0(F)
0.8(F)
0.5
0.5
0.5
0.0
C3H-lpr 4—7 3 2.5(F)C 1.5
C3H-++ 4—7 5 0.5(F) 0.5
Paraffin embedded kidneys were stained for the presence of TNF-cs.
a Grade = 0, not detectable; 1, weak; 2, moderate; 3, intense. Abbrevi-
ation F is focal. Values = x saM; all SEM were below 0.5.
bMRLlpr (4-7 days) vs. MRL-++ and C3H-++, P < 0.05
C3H-lpr (4—7 days) vs. C3H-++, P < 0.05
Table 3. TNF-cs expression on TEC is enhanced by mononuclear cell
infiltrates in MRL-lpr
TEC MNC
MRL-lpr
age months
C3H-lpr
4 5 5
+ -- 2.6 0.2C 2.8 0.2
+
Backgroundb
— 1.5 0.2
0.1 0.1
1.7 0.2
0.3 0.1
1.5 0.2
0.3 0.1
Paraffin embedded kidneys were stained for the presence of TNF-a.
Abbreviation MNC is mononuclear cell infiltrates. MP..L-lpr 4 or 5
months: MNC (+) vs. MNC (—) P < 0.05.
C TEC were evaluated in 10 separate areas MNC
b Normal rabbit IgG
C Grade = 0, not detectable; 1, weak; 2, moderate; 3, intense
d No MNC infiltrates
Values = x SEM.
Mouse
Strain Age n Upa TECb Glom PVI VSMC
MRL-lpr 2 weeks
6 weeks
3 months
4 months
>5 months
6
6
4
5
4
0.5
0.5
1.2
2.2
3.5
1.5(F)
1.7(F)
2.5
2.5C
3.0C
0
0.5
1.0
1.5C
2.0C
0
0
1.0
2.OC
3.0C
1.0
1.5
1.5
1.7
3.OC
MRL-++ 6 weeks
>4 months
7
4
0.5
1.0
1.3(F)
1.0
0.5
0.8
0
0
1.3
1.7
C3H-lpr 6 weeks
>4 months
3
2
0.5
1.0
1.0(F)
1.5
0.5
0.5
0
0
1.0
1.5
C3H-++ 6 weeks
>4 months
5
3
0.5
1.0
0.5(F)
0.5
0.5
0.5
0
0
1.0
1.0
Paraffin embedded kidneys stained for the presence of TNF-n. Values
= x SaM, all SEM were below 0.5. Abbreviations are F, focal; Glom,
glomeruli; PVI, perivascular infiltrates; VSMC, vascular smooth muscle
cells.
a Urinary protein, 0.5 = trace, 1 = 30 mg/dl, 2 = 100 mg/dl, 3 = 300
mg/dl, 4 =
2,000 mgldl (value 2 are pathological proteinuria)b Grade = 0, not detectable; 1, weak; 2, moderate; 3, intense
CMRLlpr (4-5 months) vs. MRL-++, C3H-lpr, and C3H-++ (>4
months), P < 0.05
Table 2. Renal TNF-a expression increases with progresive renal injury 1 000
in MRL-lpr mice
100
U)
a)
>
ci)
U-
10
C3H/Fej MRL-lpr CS3.1 M3.1 p388
TEC (primary) TEC (lines) Macrophage
cell line
Fig. 3. TNF-a production in primary cultured TECs and TEC cell lines(M3.1 and CS3.1) derived from MRL-lpr and C3H-+ + mice. Confluent
TECs and p388 cells (1 x 105/well) were stimulated for 24 hours with LPS
(1 g/ml, U), IL-la (100 nglml, ) and CSF-1 (10 ng/ml, D). Results are
means of triplicate samples and representative of two experiments.
Stimulated vs. unstimulated cells are P < 0.05 and P < 0.01. Constitutive
production of TNF-cs by TEC was similar in primary cultured and TEC
lines derived from MRL-lpr or C3H-+ + mice. TNF-a production was
increased in TEC by stimulating with LPS or IL-la. TNF-a production
was similarly inducible in MRL-lpr and C3H-+ + mice. In contrast, CSF-1
did not induce TNF-cc in TEC. As a control, the macrophage cell line
P388D1 was stimulated with LPS, IL-la or CSF-1 and produced increased
amounts of TNF-cs.
infiltrates also expressed TNF-a. TNF-a expression was also
detected by this procedure in the majority of mononuclear cells in
the enlarged spleens of MRL-lpr and C3H-/pr mice.
TEC derived from MRL-lpr and C3H-++ mice secrete similar
amounts of TNF-a
TNF-a in the supernatants of primary cultured TEC from
MRL-lpr mice (4 1 pg/mi) or C3H- + + mice (8 5 pg/ml) three
months of age were similar (Fig. 3). TNF-a production was readily
glomerular mesangial cells and vascular smooth muscle cells was
similar in MRL-lpr, MRL-+ +, C3H-/pr and C3H-+ + mice.
Enhanced renal TNF-a expression increases with progressive renal
injury in MRL-lpr mice
The kidneys of MRL-lpr mice with proteinuria displayed a more
diffuse and intense TNF-a as compared to MRL-lpr mice with
normal urinary protein levels and age and sex matched MRL- + +
as C3H-++ mice (Table 2). This increased expression was
particularly notable in the TEC, glomeruli, vascular smooth
muscle and perivascular infiltrating cells (Table 2). The majority
(50 to 60%) of TEC which expressed TNF-a were positive for
alkaline phosphatase reaction. By comparison, renal TNF-a ex-
pression was similar in MRL-+ +, C3H-lpr and C3H-+ + mice. In
addition, we detected greater TNF-a expression in TEC sur-
rounded by mononuclear cellular infiltrates as compared to TEC
in areas without these infiltrates (Fig. 2, Table 3). Furthermore a
large proportion (30 to 50%) of these perivascular mononuclear
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Fig. 4. The clearance of exogenous murine and
human TNF-a was similar in MRL-lpr (•),
MRL- + + (0) and C3H- + + (IiJ) mice. To
investigate the ability of TNF-R1 and TNF-R2
to remove TNF.-a from the circulation, we
injected (A) recombinant mouse (250 ng) or,
(B) recombinant human (500 ng) TNF-a (i.p.)
into C3H-+ +, MRL-+ + and MRL-lpr mice of
2 months of age. The clearance rate of mouse200 and human TNF-a was similar in MRL-lpr,
MRL-++ or C3H-++ mice. Values = x SEM
(N = 5, at each point).
increased with either LPS, IL-la, but not CSF-1 and similar in the
MRL-/pr and C3H-+ + strains. In addition, spontaneous and
stimulated TNF-a production was similar in TEC cell lines (M3.1
and CS3.1) and primary cultured TEC. The macrophage cell line,
P388D1, was used as a positive control.
Clearance of exogenous murine and human TNF-a is similar in
MRL-lpr, MRL- + + and C3H- + + mice
The levels of bioactive TNF-a after injection and the time
required to remove mouse and human recombinant TNF-a were
virtually identical in MRL-lpr, MRL- + + and C3H- + + mice (Fig.
4 A, B). The calculated clearance time (=t112) was 80 to 94
minutes and 40 to 51 minutes for mouse and human TNF-a,
respectively. Thus, since the clearance of TNF-a via TNF recep-
tors (TNF-R1 and TNF-R2) was similar in MRL-lpr, MRL-++
and C3H-++ mice, enhanced serum TNF-a does not appear to
be a consequence of a defect in the clearance.
Discussion
In this study we reported a biphasic increase in TNF-a in the
circulation and kidney of autoimmune MRL-lpr mice. The first
phase increase detected in neonatal mice is transient, disappears
after several weeks and is associated with the presence of the lpr
gene. In contrast, the second phase increase is related to the
severity of renal tissue injury. In neonates up-regulated TNF-a
expression is restricted to TEC, while TNF-a expression in mice
with progressive lupus nephritis is more broadly and abundantly
expressed to include TEC, vascular smooth muscle cells, mono-
nuclear infiltrating cells, glomerular epithelial cells and cells in the
mesangial area. It is of interest that the temporal expression of
TNF-a during each phase in the kidney and circulation are
similar.
The increase in TNF-a in the kidney and circulation during the
second phase can be explained by evolving renal injury. Our
previous studies established an increase in TNF-a proportional to
the progression of renal injury in MRL-lpr mice [3], identified a
secreted and a membrane bound form of TNF-a following the
stimulation of TEC in normal kidneys [18, 201, and reported that
macrophages accumulating in the glomeruli of mice with lupus
nephritis expressed high levels of TNF-a transcripts [11j. We have
now identified which intrarenal cells are responsible for secreting
TNF-a during progressive increase of this cytokine in the kidney
and circulation proportional to the increase in severity of renal
injury. Since we previously established that renal injury can be
accelerated by administering TNF-a systemically once renal injury
is initiated, we would predict that the persistent exposure of this
cytokine via the circulation or intrarenally is detrimental to the
kidney [4]. Enhanced expression of cytokines during renal injury is
not limited to TNF-a; we have reported an increase in CSF-1,
TGF-J3 and IL-i in the kidney as well as an abundance of CSF-i
in the circulation [3, 10—11, 19]. We have determined that the
kidney is the major source of circulating CSF-i since transplanting
a MRL-lpr kidney with mild nephritis into a bilateral nephrecto-
mized congenic strain (MRL-+ +) causes an increase in CSF-1 in
the circulation of non-autoimmune recipient. We would predict
that during progressive renal destruction that the circulation is a
reservoir for many cytokines that are being pumped out of this
damaged tissue undergoing autoimmune attack. In support on this
concept, it is interesting to note that the temporal expression of
increased TNF-a in the kidney and circulation are similar. We are
currently measuring elevations in the circulation of many of the
cytokines known to increase within the kidney during murine
lupus nephritis and investigating whether the kidney alone is the
source responsible for an increase of these cytokines in the serum.
Increasing evidence supports the concept of a regulatory defect
for cytokines in MRL-lpr mice. In fact, over a decade ago several
of the original studies investigating mechanisms of autoimmune
injury in this strain reported a defect in the production of IL-2
[221. More recent findings note enhanced TNF-a and IL-1f3 gene
expression [3], an increase in the production of TNF-a in Kupifer
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cells of MRL-lpr mice [23] and an increase of TNF-a transcription
and production in T cells in mice with the lpr mutation [24, 25]. To
identify the primary cytokine defect and distinguish it from a
secondary response, it is important to identify cytokine expression
during the earliest stages of development. Therefore, we have
investigated the production of cytokines beginning in newborn
mice. We have previously established an increase in serum CSF-1
in the circulation of MRL-lpr neonates [10]. We now document a
similar increase in TNF-a, not only in the circulation, but also
expressed by TEC in the kidney. This temporal expression of peak
TNF-a levels is similar in the circulation and kidney. While
increased CSF-1 expression in neonates is occurs in MRL-lpr but
not other strains with the lpr mutation and, therefore, is not linked
to the lpr gene, TNF-a is overexpressed in neonates in strains
bearing lpr. At least in adult MRL-lpr kidneys, CSF-1 is not
constitutively overexpressed, but dependent on a stimulus, such as
TNF-a, to induce this cytokine. This is based on experiments in
which a transplanted MRL-lpr kidney placed into a bilaterally
nephrectomized MRL-+ + recipient loses the capacity to increase
serum CSF-1 after several weeks, indicating a circulating stimu-
lant in the MRL-lpr mouse is required for persistent production of
this cytokine (manuscript in preparation). In support of this
concept, TNF-cs is not constitutively overexpressed in TEC de-
rived from MRL-lpr mice three months of age, suggesting that
TNF-a may also be up-regulated in response to at least another
stimulant in adult mice. Since CSF-.1 cannot induce TNF-a but
TNF-a induces CSF-1, it is unlikely that upregulation of CSF-1
precedes TNF-cr. It is, therefore, more plausible that overexpres-
sion of TNF-a may be attributed to a primary regulatory defect.
This concept is bolstered by the association of neonatal expression
of TNF-cs with the presence of the lpr mutation. It should also be
noted that in neonates TNF-a expression is mild and diffusely
expressed in TEC, while this expression is further increased in
TEC surrounded by infiltrating mononuclear cells in adult MRL-
lpr mice. It is possible that there is a primary regulatory defect
which is influenced by cytokines released by the mononuclear cells
invading the kidney. Future studies will test the hypothesis that
there is a regulatory defect in TNF-a which is responsible for
inducing lupus nephritis.
Since an increase in circulating levels of TNF-a could be caused
by overproduction and/or impaired removal, we explored the
possibility that MRL-lpr mice had a defective clearance of this
cytokine. Bioactive TNF-cw is rapidly removed from circulation in
a two step process; first the molecule is biologically inactivated by
binding to the circulating soluble form of TNF-R and then the
TNF-TNF-R complex is cleared from circulation [261. Recent
studies indicate that the removal of TNF-TNF-R is dependent on
the kidney, since following bilateral nephrectomy of normal mice
TNF-TNF-R complex cannot be cleared from circulation [26]. We
evaluated the removal of TNF-a by injecting either mouse or
human TNF-a into mice at two months of age. We selected this
age since circulating TNF-a is at its nadir in MRL-lpr mice and
would not obscure evaluation of the clearance rates, and because
this is a period prior to overt renal injury. We can determine
whether the TNF-a clearance is related to the 55 kDa receptor
(TNF-R1) and/or the 77 kDa receptor (TNF-R2), since mouse
TNF-R1 binds to both mouse and human TNF, while mouse
TNF-R2 binds exclusively to mouse TNF [21]. Since either form
of TNF-a had a similar clearance rate in MRL-lpr, congenic
MRL-+ + or C3HIFej strains, we conclude that the clearance of
TNF-a is not impaired in these adult mice prior to the loss of
renal function.
Lymphoid abnormalities, a central feature of mice with the lpr
mutation, may be directly introduced by overexpression of TNF-a.
This is based on studies reporting that anti-mouse TNF-a anti-
bodies initiated during pregnancy or at the birth, result in a
marked atrophy of the thymus, spleen, lymph nodes, lymphopenia
and impaired development of T and B cell peripheral lymphoid
structures [27]. It is of interest that all strains with the lpr gene
have a prominent lymphoid proliferation consisting of a unique T
cell which accumulate predominantly in the spleen, lymph nodes
and kidney [10, 24, 25, 28, 29]. Thus, an overproduction of TNF-a
may cause the expansion of these lymphoid cells. In addition, the
Fas antigen is absent in strains with the lpr mutation and may be
responsible for failure to delete this unique type of T cell [30].
Since the Fas antigen belongs to the same TNF-a receptor family
[12, 13, 16], it will be important to clarify the relationship between
the inability to express this antigen and overexpression of TNF-a.
Further experiments will also be directed towards understanding
the importance of an increase in TNF-a in neonates in this
autoimmune strain with lymphocyte abnormalities.
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